European Commission Tafamidis (Vyndaqel) for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Approval of this transthyretin stabiliser was based on the Phase 3 ATTR-ACT study which found a significant reduction in the hierarchical combination of all-cause mortality and frequency of cardiovascular-related hospitalisations vs placebo over a 30-month period (p=0.0006).
Source:
Biospace Inc.